U.S. health advisers are deliberating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective for 5- to 11-year-olds. Tuesday's meeting of the FDA panel is the first step toward expanding vaccinations to 28 million youngsters. (Oct. 26)

Subscribe for more Breaking News: http://smarturl.it/AssociatedPress
Website: https://apnews.com
Twitter: https://twitter.com/AP
Facebook: https://facebook.com/APNews
Instagram: https://www.instagram.com/APNews/
​

You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/91902f3af66447fd9e9723f42ca7111c